Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies

Authors:
Open Access
Publisher website
Google Scholar
Abstract
The global prevalence of obesity is rapidly in creasing, significantly increasing the incidence of heart failure with preserved ejection fraction (HFpEF). Obesity, one of the most common clinical phenotypes of HFpEF, facilitates the onset and progression of HFpEF via multiple pathophysiological mechanisms. Lifestyle intervention, which serves as the cornerstone of weight loss, plays a crucial role in the management of HFpEF. Novel antidiabetic therapies, including sodium glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and glucose‒dependent insulinotropic polypeptide (GIP)/glucagon‒like peptide-1 (GLP-1) dual receptor agonists, have favourable effects on clinical outcomes in obese HFpEF patients. For patients with heart failure (HF) prior to bariatric surgery (BSx), there is moderate evidence supporting the efficacy and safety of the procedure. This review systematically summarizes the clinical evidence related to metabolic therapy treatment strategies for obese HFpEF patients and discusses the potential advantages of such therapy.
Funding Information
  • Jiaxing Science and Technology Program (Grant No.2023AD31022, Grant No.2023AD31022, Grant No.2023AD31022)
  • National Natural Science Foundation of China (No. 82300363)
  • Zhejiang Province Clinical Key Specialty Construction Project (2024-ZJZK-001, 2024-ZJZK-001)
  • Zhejiang Province Traditional Chinese medicine scientific research fund (2023ZL700)

This publication has 173 references indexed in Scilit: